EUVIMEDEUVIMED entdecken
Crossref

From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets

Zachary White, Bradley Brooks, Steven Cox

Business Case Journal · 12.08.2026 · 33 (1) · 74

DOI: 10.69521/bcj.v33i1.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Business Case Journal, online erschienen am 12.08.2026. Verfasst von Zachary White und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novo Nordisk boasted two highly successful pharmaceutical brands, Ozempic and Wegovy. Each brand contained the same active ingredient (semaglutide). However, Ozempic was positioned as a diabetes treatment, while Wegovy was positioned as a weight loss treatment. Both brands faced challenges of building brand equity while competing in a competitive but growing market. The student is ultimately asked to design a plan moving forward amidst the challenges of managing popular brands.

Zitieren

APA

White, Z., Brooks, B., & Cox, S. (2026). From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets. Business Case Journal, 33(1), 74. https://doi.org/10.69521/bcj.v33i1.5

Vancouver

White Z, Brooks B, Cox S. From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets. Business Case Journal. 2026;33(1):74. doi:10.69521/bcj.v33i1.5

BibTeX
@article{White2026,
  author = {White, Zachary and Brooks, Bradley and Cox, Steven},
  title = {From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets},
  journal = {Business Case Journal},
  year = {2026},
  volume = {33},
  number = {1},
  pages = {74},
  doi = {10.69521/bcj.v33i1.5}
}
Kostenlos starten →